Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the effect of highly accelerated external beam radiotherapy (EBRT) in 5 fractions over 10 days compared to 15 fractions over 3 weeks for early as well as locally-advanced stage breast cancer. Primary endpoint will be chronic toxicity (breast deformation and retraction). Secondary endpoints are acute toxicity, loco-regional and distant tumor control, patient reported QoL and cosmetic satisfaction. Patients with lymph node irradiation will be closely monitored for radiation induced plexopathy.

Clinical Trial Description

Over the age of 65, uptake of adjuvant radiotherapy after surgery for breast cancer declines, even in women with poor prognostic stage or adverse tumor characteristics. Lowering the number of fractions may reduce reluctancy for radiotherapy in this age group. In a preceding prospective phase I-II trial, evaluating EBRT over 10 days, results on technical feasibility and acute toxicity were positively evaluated. However, data on the chronic effects of breast irradiation using high doses per fraction are still sparse. This trial is developed to compare standard hypo-fractionation in 15 fractions (if needed with simultaneously integrated boost - SIB) with highly accelerated radiotherapy in 5 fractions. Patients referred for adjuvant radiotherapy after breast conserving surgery will preferably be randomized, depending on the indication, to a study-arm with whole breast irradiation (WBI) +/- SIB or to a study-arm with WBI+/- SIB and lymph node irradiation (LNI). If patients after breast conserving surgery (BCS) have a strong preference for 5 or 15 fractions, they will be invited to enter the parallel observational arm (patient preference). Patients referred for adjuvant radiotherapy after mastectomy +/- LNI accepting to participate, can choose a 5 or 15-fraction schedule. No randomization is foreseen in this last observational group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03121248
Study type	Interventional
Source	University Hospital, Ghent
Contact
Status	Active, not recruiting
Phase	N/A
Start date	February 15, 2017
Completion date	November 15, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02944604` - The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy	Phase 4
Completed	`NCT03012152` - A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction	N/A
Terminated	`NCT04168957` - An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007	Phase 1
Recruiting	`NCT02967146` - Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer	Phase 3
Completed	`NCT02958332` - Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer	N/A
Completed	`NCT03030677` - Establishing Technique for PECS2 Catheter Insertion	N/A
Completed	`NCT03165955` - A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients	Phase 1
Completed	`NCT03066947` - SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT02992574` - Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer	N/A
Completed	`NCT02964234` - Empowering Latinas to Obtain Breast Cancer Screenings	N/A
Completed	`NCT02996240` - Breast, Omega 3 Free Fatty Acid, Ph 0	N/A
Completed	`NCT03010371` - Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.	N/A
Completed	`NCT02209857` - The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy	N/A
Completed	`NCT03014076` - Immunotherapy Vaccine and Herceptin in Breast Cancer	Phase 1
Terminated	`NCT02975128` - Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance	N/A
Active, not recruiting	`NCT02997384` - Feasibility of Breast Cancer Risk Evaluation in Women From the General Population	N/A
Completed	`NCT03012893` - Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan.	N/A
Completed	`NCT03023007` - Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy	N/A
Completed	`NCT04993040` - A PK Study of Oraxol in Breast Cancer Patients	Phase 1
Completed	`NCT02992067` - CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years — HAI-5-III

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms